Compared to durvalumab and atezolizumab, avelumab can, in addition to PD-L1 inhibition, induce antibody-dependent cell mediated cytotoxicity (ADCC), which results in a direct lysis of tumor cells [22]. The gene discussed is CD274; the disease is neoplasm.